Menu
More than six people die every hour in the US from a blood cancer. Solutions can’t come fast enough for those who suffer with these cancers all around the world. Fortunately, researchers studying blood diseases have experienced rapid advances in their capabilities to develop and test effective therapies with some extremely significant advancements.
Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a new era of precision efficiency². This blog explores how predictive analytics is transforming clinical trials, from optimizing design and recruitment to predicting outcomes and reducing risks.
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹⁻³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company. The posters provided real-world data insights on the genomic landscape of specific biomarkers associated with lung and prostate cancers, in a subset of European countries. The first poster spotlight features […]
See how Henry Ford Health enhanced their genetic testing by adopting exome sequencing for hereditary cancer, cystic fibrosis, and pharmacogenetics applications.
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow.
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.
We recently spoke with Manuela Badiali, Rita Congiu, and Stefania Murru from the Laboratory of Genetics and Genomics, Microcitemico Pediatric Hospital – A. Cao, Cagliari, about how SOPHiA DDM™ RNAtarget Technology has helped them optimize their variant analysis workflow.
Memorial Sloan Kettering Cancer Center (MSK) is a world leading institution for cancer treatment and research. We’re collaborating with MSK to expand access to precision cancer analysis capabilities worldwide.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.